Anivive Lifesciences is a pioneering brand that accelerates the development of new medicines to ensure that our beloved pets can lead happier and healthier lives. Committed to the well-being of our furry companions, Anivive focuses on solving the unmet needs of the animal health community through the use of advanced technology and intelligent treatments. They employ end-to-end software solutions to expedite drug development and find innovative solutions for veterinary therapeutics.

Anivive is currently working towards USDA conditional licensure for an anti-fungal vaccine, which could potentially become the first approved anti-fungal vaccine for any species. Backed by a team of seasoned entrepreneurs, pet industry executives, and software innovators, Anivive has garnered over 85 FDA approvals, overseen 1,200+ animal studies, and published 650+ peer-reviewed publications. Investors can stay informed with timely business updates and accounting reports from the CFO via Anivive's investor relations section.

Located in Long Beach, CA, Anivive Lifesciences is more than just a pet pharmaceutical company. Their groundbreaking discoveries and innovations bring lasting hope to families in need